Abstract:Type 2 diabetes is a progressive and complex condition that is difficult to cure in log run. α-Glucosidase inhbitors seems to be most effective in the treatment of diabtes. β-lactams reported for few antidiabetic property with α-glucosidase inhibitory activity. The current study aims at evaluating the potential of newly synthesized β-lactams B8-B14 as α-glucosidase inhibitors which can help in controlling the high blood glucose level in type 2 diabetes mellitus. Herein, the synthesized 3-nitrophenyl imine derivatives (1 eq.) reacted with ethenone (1 eq.) in benzene by staudinger cycloaddition reaction to afford the synthesis of β-lactams B8-B14 and confirmed by advanced spectroscopic techniques and elemental analysis. The antihyperglycemic studies revealed that compounds (B8, B9, B12-B14) at a dosage of 5 mg/kg and after 24 h of administration showed higher percentage of decrease in blood sugar (12.61-21.07%) than reference drug glibenclamide (11.74%). In line with in vitro studies, β-lactams B8 and B9 proved as potent inhibitors of α-glucosidase enzyme with IC50 values 3.33 μM and 2.21 μM respectively higher than standard drug acarbose (IC50= 5.47 μM). Further, in vivo experiment confirmed that the most potent antidiabetic agents B8 and B9 significantly decrease the ALT level (71.1-74.3%) to prevent the liver injury induced by diabetes. The higher antioxidant potential confirmed the role of B9 as lead antidiabetic agent to manage the ROS generated by diabetes. Autodock vina used to identify the catalytic sites of α-glucosidase and to remove water molecules and add hydrogen and kollman charges to protein structure. In molecular docking studies, B9 tightly fit within the catalytic pocket of the α-glucosidase enzyme with a binding affinity of -9.1 kcal/mol that supported its potential as a strong α-glucosidase inhibitor. The most potent compound B9 found to have optimal lipophilicity (2.63), highest druglikeness (86.9%) and excellent gastrointestinal absorption that are suitable for bioavailability and drug design. Moreover these physiochemical properties also showed excellent correlation of to the α-glucosidase inhibitory and antidiabetic activity. Overall, these excellent results suggest that the most potent compound B9 has the potential to develop as a therapeutic drug in the future to treat diabetes with α-glucosidase inhibitory activity.

Synthesis and Biological Evaluation of β-lactams as Potent Antidiabetic Agents

Potent α-glucosidase inhibitors with benzimidazole-propionitrile hybridization; synthesis, bioassay and docking study

Integrative bioinformatic and experimental analysis of benzoylbenzodioxol derivatives: hypoglycemic potential in diabetic mice

Acyl pyrazole sulfonamides as new antidiabetic agents: synthesis, glucosidase inhibition studies, and molecular docking analysis

A Combined Experimental and Computational Study of Novel Benzotriazinone Carboxamides as Alpha-Glucosidase Inhibitors

Synthesis, in vitro biological assessment, and molecular docking study of benzimidazole-based thiadiazole derivatives as dual inhibitors of α-amylase and α-glucosidase

Synthesis, highly potent α-glucosidase inhibition, antioxidant and molecular docking of various novel dihydropyrimidine derivatives to treat diabetes mellitus

Ultrasound-assisted synthesis of 4-thiazolidinone Schiff bases and their antioxidant, α-glucosidase, α-amylase inhibition, mode of inhibition and computational studies

Molecular docking, chemo-informatic properties, alpha-amylase, and lipase inhibition studies of benzodioxol derivatives

Exploring the synthesis, molecular structure and biological activities of novel Bis -Schiff base derivatives: A combined theoretical and experimental approach

Synthesis, antidiabetic activity and in silico studies of benzo[ b ]thiophene based small molecule α-amylase inhibitors

Synthesis, molecular docking and DFT analysis of novel bis-Schiff base derivatives with thiobarbituric acid for α-glucosidase inhibition assessment

Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting α-amylase, and α-glucosidase: synthesis, molecular docking, and ADMET studies

Dual active pyrimidine-based carbocyclic nucleoside derivatives: synthesis, and in silico and in vitro anti-diabetic and anti-microbial studies

Discovery of new anti-diabetic potential agents based on paracetamol incorporating sulfa-drugs: Design, synthesis, α-amylase, and α-glucosidase inhibitors with molecular docking simulation

Synthesis, characterization and molecular modeling approach of hybrid pyrazole based thiazolidinone derivatives: An estimation and inhibition of diabetes mellitus

Synthesis of the chromone‐thiosemicarbazone scaffold as promising α‐glucosidase inhibitors: An in vitro and in silico approach toward antidiabetic drug design

Synthesis of Flurbiprofen Based Amide Derivatives as Potential Leads for Diabetic Management: In Vitro α‐glucosidase Inhibition, Molecular Docking and DFT Simulation Approach

Synthesis of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives as potential glucosidase inhibitors

Identification of isobenzofuranone derivatives as promising antidiabetic agents: Synthesis, in vitro and in vivo inhibition of α -glucosidase and α -amylase, computational docking analysis and molecular dynamics simulations

Exploring Thiazolidinedione-Naphthalene Analogues as Potential Antidiabetic Agents: Design, Synthesis, Molecular Docking and In-vitro Evaluation